Welcome to our dedicated page for BIODESIX news (Ticker: BDSX), a resource for investors and traders seeking the latest updates and insights on BIODESIX stock.
Biodesix Inc (BDSX) generates news across diagnostic testing developments, biopharmaceutical partnerships, and clinical validation studies in the lung disease diagnostics sector. As a precision medicine company operating a dual-platform business model, Biodesix's news coverage reflects both its commercial diagnostic testing activities and its research collaborations with pharmaceutical companies.
Diagnostic testing news for Biodesix typically includes updates on test adoption rates, new clinical evidence supporting the utility of its blood-based lung diagnostics, and expansions in insurance coverage or reimbursement policies. The company's Nodify and IQLung testing platforms serve healthcare providers making critical decisions about lung nodule management and cancer treatment, so clinical validation studies and real-world evidence publications represent material developments. Coverage also extends to regulatory milestones such as laboratory certifications and quality accreditations that enable the company to offer diagnostic services.
Biopharmaceutical development services news focuses on contract announcements with pharmaceutical companies, companion diagnostic collaborations, and clinical trial partnerships. These relationships can significantly impact the Development Services segment's revenue trajectory and demonstrate the company's scientific capabilities in biomarker discovery and diagnostic development. News about successful companion diagnostic approvals or clinical trial results using Biodesix's services validates the company's expertise in precision medicine applications.
Financial reporting represents a key news category, with quarterly earnings releases providing insights into test volume trends, revenue performance across the dual business segments, gross margin evolution, and progress toward profitability targets. Investor presentations and strategic updates outline management's vision for expanding market penetration in pulmonology and primary care settings. Technology and scientific news covers advancements in AI-based diagnostic algorithms, multi-omics analysis capabilities, and new biomarker discoveries that could inform future product development.
Biodesix (Nasdaq: BDSX) reported preliminary, unaudited results for Q4 and full-year 2025. Estimated Q4 revenue $28.8M (+41% YoY) and FY2025 revenue $88.5M (+24% YoY), above prior guidance range of $84–$86M. Lung Diagnostics revenue estimated at $25.2M (Q4) and $79.2M (FY), driven by higher test volumes, price per test, and ~$1.0M in collections on claims >1 year. Test volumes were an estimated 18,000 (Q4) and 62,600 (FY). Development Services revenue was estimated at $3.6M (Q4) and $9.3M (FY). Cash and cash equivalents were ~$19.0M at 12/31/2025, including $2.3M of at-the-market proceeds. The company affirmed its expectation of positive Adjusted EBITDA in Q4 2025. Results remain preliminary and subject to audit.
Biodesix (Nasdaq: BDSX) announced poster presentations of new clinical and development data at two scientific meetings in December 2025. At NACLC (Dec 5–7, Chicago) the company will present post‑market Nodify Lung® data that address timely lung nodule risk classification and modeling of autoantibody testing impact on time to lung cancer diagnosis. At SABCS (Dec 9–12, San Antonio) Biodesix will present development data for an ultra‑sensitive ESR1 droplet digital PCR test for detecting and monitoring ESR1 variants in HR+/HER2‑ advanced breast cancer; the test is offered to biopharmaceutical customers via Development Services. The company also received two recognitions at ISPOR Europe 2025 for research on pulmonary nodule follow‑up and related healthcare costs, to be published in the December supplement of Value in Health.
Biodesix (NASDAQ: BDSX) reported Q3 2025 revenue of $21.8M, up 20% year‑over‑year, and a gross margin of 81%, a 400‑basis‑point improvement versus Q3 2024. Development Services revenue grew 97% YoY and dollars under contract reached $12.9M. The company raised full‑year 2025 revenue guidance to $84–86M and expects to reach Adjusted EBITDA positivity in Q4 2025. Q3 net loss narrowed to $8.7M; cash and equivalents were $16.6M at quarter end, impacted by a $5.2M increase in accounts receivable.
Management cited primary care expansion, payer improvements, and a Bio‑Rad partnership as drivers.
Biodesix (Nasdaq: BDSX) will present its R&D Roadmap at the 2025 AMP Annual Meeting in Boston, Nov 12-15, 2025. On Nov 12 at 4:00 PM ET, Dr. Gary Pestano will lead a Corporate Workshop on near- and longer-term diagnostic services, featuring partners Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher Scientific.
The workshop focuses on molecular testing advances (NGS, ddPCR, Mass Spectrometry) emphasizing rapid turn-around, high throughput, and low sample requirements; a recording will be posted on the company website. Biodesix staff will staff booth #647, and a poster on circulating tumor cell enrichment will be presented on Nov 15.
Biodesix (NYSE:BDSX) announced on Oct 22, 2025 an expanded partnership with Bio-Rad to develop, clinically validate, and pursue regulatory clearance for Droplet Digital PCR (ddPCR) in vitro diagnostic assays on Bio-Rad's QX600 platform.
Key first-step work includes validation of Bio-Rad's ddPLEX ESR1 Mutation Detection Assay for HR+/HER2- advanced breast cancer, manufacturing and distribution of specimen collection kits after clearance, offering the assay as a test at Biodesix's CLIA-CAP laboratory, and seeking CMS reimbursement. Both companies will present further details at AMP, Nov 11-15, 2025 in Boston.
Biodesix (Nasdaq: BDSX) will release third quarter financial results for the period ended September 30, 2025 after market close on Monday, November 3, 2025. Management will host a conference call and webcast at 4:30 p.m. Eastern Time the same day to discuss results and provide a business update. Registration links are provided for listeners and participating analysts. A replay will be available on the company investor website approximately two hours after the call ends. Participants are advised to join 15 minutes before the start time.
Biodesix (Nasdaq: BDSX) announced presentations and events at the CHEST 2025 Annual Meeting, October 19–22 in Chicago. Preliminary CLARIFY study data from the first 1,000 enrolled patients will be presented in a sponsored Learning Theater on October 21 at 2:00 PM CDT by Michael Kammer, PhD.
The CLARIFY study is a real-world retrospective review designed to assess Nodify CDT and Nodify XL2 performance in up to 4,000 patients with ≥1-year follow-up. Multiple independent clinical presentations and a national analysis of pulmonary nodule healthcare resource utilization will also be presented. Biodesix leadership will staff booth #1012.
Biodesix (Nasdaq: BDSX) announced three Colorado lung‑health events in October 2025 aimed at clinicians and the community to advance education and advocacy. Oct 9 — APAPP Know Your Nodules, a half‑day clinician program at Biodesix headquarters in Louisville with live streaming and faculty from Vanderbilt, Henry Ford, and regional providers. Oct 9–11 — Go2 for Lung Cancer Centers of Excellence Summit in Denver, featuring a full‑day Lung Cancer Nurse Navigator module; Biodesix is a sponsor. Oct 12 — American Lung Association Run the Rocks fundraiser at Red Rocks Amphitheater in Morrison to raise funds for lung health education, research, and advocacy.
The company framed these events as local advocacy ahead of November Lung Cancer Awareness Month.
Biodesix (NASDAQ:BDSX) has announced a one-for-twenty reverse stock split effective September 15, 2025. The split will reduce the company's outstanding shares from approximately 156 million to 8 million, while maintaining the same authorized shares and par value.
The reverse split was approved by stockholders on May 20, 2025, and will be executed through Computershare Trust Company. Stockholders' percentage ownership will remain unchanged except for fractional shares, which will be paid in cash. All equity incentive plans, stock options, restricted stock units, and warrants will be proportionally adjusted.
Biodesix (NASDAQ:BDSX), a diagnostic solutions company, announced that CFO Robin Cowie will participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth Conference on September 11, 2025, in New York. The CFO will be available for one-on-one meetings with investors during the conference.
FAQ
What is the current stock price of BIODESIX (BDSX)?
What is the market cap of BIODESIX (BDSX)?
